Actuarial science

$495 Million Worldwide Drug and Gene Delivery Devices Industry to 2027 - Impact Analysis of COVID-19 - ResearchAndMarkets.com

Tuesday, July 27, 2021 - 11:33am

The "Drug and Gene Delivery Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug and Gene Delivery Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Drug and Gene Delivery Devices estimated at US$495 Billion in the year 2020, is projected to reach a revised size of US$767.3 Billion by 2027, growing at a CAGR of 6.5% over the analysis period 2020-2027.
  • Oral, one of the segments analyzed in the report, is projected to record a 6.3% CAGR and reach US$366.8 Billion by the end of the analysis period.
  • In the global Transdermal segment, USA, Canada, Japan, China and Europe will drive the 6.3% CAGR estimated for this segment.

Insights on the 3D Food Printing Industry to 2027 - Featuring Barilla, Choc Edge and Nu Food Among Others - ResearchAndMarkets.com

Tuesday, July 27, 2021 - 11:29am

The "3D Food Printing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "3D Food Printing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Fruits & Vegetables, one of the segments analyzed in the report, is projected to record a 17.2% CAGR and reach US$500.6 Million by the end of the analysis period.
  • In the global Carbohydrates & Proteins segment, USA, Canada, Japan, China and Europe will drive the 13.4% CAGR estimated for this segment.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$157 Million by the year 2027.

Global Oral Thin Films Industry (2020 to 2027) - Key Market Trends and Drivers - ResearchAndMarkets.com

Tuesday, July 27, 2021 - 11:22am

The "Oral Thin Films - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oral Thin Films - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Oral Thin Films estimated at US$2.6 Billion in the year 2020, is projected to reach a revised size of US$5.9 Billion by 2027, growing at a CAGR of 12.3% over the period 2020-2027.
  • Sublingual Film, one of the segments analyzed in the report, is projected to record 11.6% CAGR and reach US$2.5 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $772.3 Million, While China is Forecast to Grow at 11.9% CAGR
    The Oral Thin Films market in the U.S. is estimated at US$772.3 Million in the year 2020.

Insights on the Flexible and Semi-Rigid Ureteroscopy Global Market to 2027 - Featuring Boston Scientific, Olympus and Stryker Among Others - ResearchAndMarkets.com

Tuesday, July 27, 2021 - 9:38am

The "Flexible and Semi-Rigid Ureteroscopy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Flexible and Semi-Rigid Ureteroscopy - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Flexible and Semi-Rigid Ureteroscopy estimated at US$844.7 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2027, growing at a CAGR of 4.9% over the period 2020-2027.
  • Flexible, one of the segments analyzed in the report, is projected to record 5.6% CAGR and reach US$872 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $227.8 Million, While China is Forecast to Grow at 8.1% CAGR
    The Flexible and Semi-Rigid Ureteroscopy market in the U.S. is estimated at US$227.8 Million in the year 2020.

Candel Therapeutics Announces Pricing of Initial Public Offering

Tuesday, July 27, 2021 - 2:05am

NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the pricing of its initial public offering of 9,000,000 shares of common stock at a public offering price of $8.00 per share.

Key Points: 
  • NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the pricing of its initial public offering of 9,000,000 shares of common stock at a public offering price of $8.00 per share.
  • The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Candel, are expected to be $72 million.
  • The offering is expected to close onJuly 29, 2021, subject to the satisfaction of customary closing conditions.
  • In addition,Candel has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Acutus Medical, Inc. Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares

Monday, July 26, 2021 - 9:01pm

The closing of the option exercise occurred on July 26, 2021.

Key Points: 
  • The closing of the option exercise occurred on July 26, 2021.
  • With the addition of the full exercise of the underwriters option to purchase additional shares, the total number of shares sold by Acutus in the offering increased to 6,325,000 shares, and the aggregate gross proceeds, before deducting underwriting discounts and commissions and other offering expenses payable by Acutus, were approximately $88.6 million.
  • Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated.
  • By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

$667.3 Million Worldwide Muscle Stimulators Industry to 2027 - Impact Analysis of COVID-19 - ResearchAndMarkets.com

Monday, July 26, 2021 - 5:34pm

Amid the COVID-19 crisis, the global market for Muscle Stimulators estimated at US$667.3 Million in the year 2020, is projected to reach a revised size of US$870.3 Million by 2027, growing at a CAGR of 3.9% over the analysis period 2020-2027.

Key Points: 
  • Amid the COVID-19 crisis, the global market for Muscle Stimulators estimated at US$667.3 Million in the year 2020, is projected to reach a revised size of US$870.3 Million by 2027, growing at a CAGR of 3.9% over the analysis period 2020-2027.
  • Transcutaneous Electrical Nerve Stimulation, one of the segments analyzed in the report, is projected to record a 4.3% CAGR and reach US$318 Million by the end of the analysis period.
  • The U.S. Market is Estimated at $180.4 Million, While China is Forecast to Grow at 6.3% CAGR
    The Muscle Stimulators market in the U.S. is estimated at US$180.4 Million in the year 2020.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$175.6 Million by the year 2027 trailing a CAGR of 6.3% over the analysis period 2020 to 2027.

Global Coffee Shops Market Report 2021: COVID-19 Crisis Leaves Coffee Shops Struggling to Contain Operating Losses - ResearchAndMarkets.com

Monday, July 26, 2021 - 4:35pm

The "Coffee Shops - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Coffee Shops - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Coffee Shops estimated at US$156.9 Billion in the year 2020, is projected to reach a revised size of US$201.4 Billion by 2027, growing at a CAGR of 3.6% over the period 2020-2027.
  • Coffee, one of the segments analyzed in the report, is projected to record 4.1% CAGR and reach US$123 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $35 Billion, While China is Forecast to Grow at 6.3% CAGR
    The Coffee Shops market in the U.S. is estimated at US$35 Billion in the year 2020.

SiriusPoint Announces Date for Second Quarter 2021 Earnings Release

Monday, July 26, 2021 - 9:10pm

HAMILTON, Bermuda, July 26, 2021 /PRNewswire/ --SiriusPoint Ltd. (NYSE: SPNT) ("SiriusPoint" or the "Company") today announced that it is planning to release its Second Quarter 2021 financial results after the market close on Thursday, August 5, 2021.

Key Points: 
  • HAMILTON, Bermuda, July 26, 2021 /PRNewswire/ --SiriusPoint Ltd. (NYSE: SPNT) ("SiriusPoint" or the "Company") today announced that it is planning to release its Second Quarter 2021 financial results after the market close on Thursday, August 5, 2021.
  • The Company will also hold a conference call to discuss its financial results at 8:30 am (Eastern Time) on Friday, August 6, 2021.
  • The conference call can be accessed by dialing 1-877-300-8521 (domestic) or 1-412-317-6026 (international) and asking for the SiriusPoint Ltd. Second Quarter 2021 Earnings Call.
  • SiriusPoint Ltd. (SiriusPoint) is a top 20 global insurer and reinsurer providing solutions to clients and brokers in almost 150 countries.

Talos Energy Provides Update On Recent Drilling Operations And Second Quarter Production

Monday, July 26, 2021 - 12:00pm

These forward-looking statements are based on our current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events.

Key Points: 
  • These forward-looking statements are based on our current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events.
  • Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, to reflect events or circumstances after the date of this communication.
  • These estimates are subject to greater uncertainties, and accordingly, are subject to a substantially greater risk of actually being realized.
  • Investors are urged to consider closely the disclosures and risk factors in the reports the Company files with the SEC.